Danaparoid

Jump to: navigation, search
Danaparoid
Clinical data
ATC code
Identifiers
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).

WikiDoc Resources for Danaparoid

Articles

Most recent articles on Danaparoid

Most cited articles on Danaparoid

Review articles on Danaparoid

Articles on Danaparoid in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Danaparoid

Images of Danaparoid

Photos of Danaparoid

Podcasts & MP3s on Danaparoid

Videos on Danaparoid

Evidence Based Medicine

Cochrane Collaboration on Danaparoid

Bandolier on Danaparoid

TRIP on Danaparoid

Clinical Trials

Ongoing Trials on Danaparoid at Clinical Trials.gov

Trial results on Danaparoid

Clinical Trials on Danaparoid at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Danaparoid

NICE Guidance on Danaparoid

NHS PRODIGY Guidance

FDA on Danaparoid

CDC on Danaparoid

Books

Books on Danaparoid

News

Danaparoid in the news

Be alerted to news on Danaparoid

News trends on Danaparoid

Commentary

Blogs on Danaparoid

Definitions

Definitions of Danaparoid

Patient Resources / Community

Patient resources on Danaparoid

Discussion groups on Danaparoid

Patient Handouts on Danaparoid

Directions to Hospitals Treating Danaparoid

Risk calculators and risk factors for Danaparoid

Healthcare Provider Resources

Symptoms of Danaparoid

Causes & Risk Factors for Danaparoid

Diagnostic studies for Danaparoid

Treatment of Danaparoid

Continuing Medical Education (CME)

CME Programs on Danaparoid

International

Danaparoid en Espanol

Danaparoid en Francais

Business

Danaparoid in the Marketplace

Patents on Danaparoid

Experimental / Informatics

List of terms related to Danaparoid

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Danaparoid sodium (Orgaran®) is an anticoagulant that works by inhibiting activated factor X (factor Xa).

Danaparoid is considered a "low molecular weight heparin" by some sources, but is chemically distinct from heparin and thus has little cross-reactivity in heparin-intolerant patients.

Uses

It is used to prevent deep venous clots, particularly in situations with a high risk of clot formation, such as after hip surgery.

It is also used as a heparinoid substitute in heparin-induced thrombocytopenia which may otherwise cause paradoxical thrombosis.

Discontinuation

On August 14, 2002, this drug was withdrawn by Organon International.[1]

Administration

Side Effects

  • Bleeding problems
  • Low platelets, due to a low level of structural similarity between danaparoid and heparin
  • Asthma exacerbations, due to allergies to sulphites contained within the medicine

External Links

References

  1. "Danaparoid (Subcutaneous Route) - MayoClinic.com".

Linked-in.jpg